Pharmacy & Acute Care University
Pharmacy & Acute Care University
Back to Course

PACULit Literature Updates September 2025: Oncology

0% Complete
0/0 Steps
  1. Immune mediated adverse events in the randomized phase 3 TOPAZ 1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer
    1 Topic
    |
    1 Quiz
  2. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma DREAMM7 updated overall survival analysis from a global randomised open label phase 3 trial
    1 Topic
    |
    1 Quiz
  3. PACULit Daily Literature Update: Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database
    1 Topic
    |
    1 Quiz
  4. PACULit Daily Literature Update: Effects of BojungikkiTang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors a randomized pilot study
    1 Topic
    |
    1 Quiz
  5. PACULit Daily Literature Update: Long acting lipegfilgrastim and antimicrobials as vigorous primary prophylaxis in bendamustine treated patients with indolent B cell non Hodgkin lymphoma a multicentric real life experience
    1 Topic
    |
    1 Quiz
  6. First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC a single-arm phase II study
    1 Topic
    |
    1 Quiz
  7. Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma
    1 Topic
    |
    1 Quiz
  8. Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
    1 Topic
    |
    1 Quiz
  9. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure
    1 Topic
    |
    1 Quiz
  10. Phase I II clinical trial on the safety and preliminary efficacy of donor derived anti leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hematopoietic stem cell transplantation study rational and design
    1 Topic
    |
    1 Quiz
  11. Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma subgroup analysis of the ECHELON2 study at 5 years followup
    1 Topic
    |
    1 Quiz
  12. Effectiveness and Safety of Immunotherapy for Hepatocellular Carcinoma in Clinical Practice A Brazilian Multicenter Study
    1 Topic
    |
    1 Quiz
  13. Talquetamab improves patient reported symptoms and health related quality of life in relapsed or refractory multiple myeloma Results from the phase 12 MonumenTAL1 study
    1 Topic
    |
    1 Quiz
  14. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
    1 Topic
    |
    1 Quiz
    1. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
  15. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non Small Cell Lung Cancer Update From the COAST Randomized Clinical Trial
    1 Topic
    |
    1 Quiz
  16. Real world patient profile and step up dosing process of early initiators of teclistamab for multiple myeloma in US hospitals An analysis using the Premier Healthcare Database
    1 Topic
    |
    1 Quiz
  17. Virtual reality for outpatient management of cancer pain a pilot dosing study
    1 Topic
    |
    1 Quiz
  18. Brentuximab vedotin plus chemotherapy for the treatment of frontline systemic anaplastic large cell lymphoma
    1 Topic
    |
    1 Quiz
  19. Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors should we treat beyond two years
    1 Topic
    |
    1 Quiz
  20. Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Nivolumab
    1 Topic
    |
    1 Quiz
  21. ACPE Required Forms: PACULit Literature Updates September 2025: Oncology
    3 Topics

Quizzes

Participants 440

  • Allison Clemens
  • April
  • ababaabhay
  • achoi2392
  • adhoward1
Show more
PACULit Literature Updates September 2025: Oncology Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
Lesson 14 of 21
In Progress

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

Elez Elena,Yoshino Takayuki,Shen Lin, et al.Encorafenib, Cetuximab, and mFOLFOX6 in The New England journal of medicine. 2025-Jun-26;392(24):2425-2437. doi:10.1056/NEJMoa2501912 | PMID: N/A

Study Type

Randomized Controlled Trial

Population

Patients with BRAF-mutated metastatic colorectal cancer

Intervention

Encorafenib, Cetuximab, and mFOLFOX6 chemotherapy

Follow-up

Median follow-up of 24 months

This phase 3 randomized study evaluated the efficacy and safety of the combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy compared to standard therapy in patients with BRAF V600E-mutated metastatic colorectal cancer, demonstrating improved overall survival and response rates.

Key Learning Points

  • •
    Combination therapy with encorafenib and cetuximab plus mFOLFOX6 significantly improves overall survival in BRAF-mutated colorectal cancer.
  • •
    The regimen is well tolerated with manageable safety profiles, representing a new standard for this patient population.


Read Full Study Review


Take Assessment Quiz



🎧 AI Audio Overview

Complete the study review and quiz to earn CE credit

Lesson Content
0% Complete 0/1 Steps